SCHEMBL23920029

SCHEMBL23920029

N#Cc1c(-c2ccccc2O)cc(-c2ccc(F)cc2)[nH]c1=N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 7/20 0.47
▸ BIRC5 O15392 3/20 0.46
▸ KMT2A Q03164 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ BCL2L1 Q07817 1/20 0.42
▸ ALDH1A1 P00352 4/20 0.41
▸ MAPT P10636 3/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ ATM Q13315 1/20 0.40
▸ GCGR P47871 1/20 0.39
▸ MAPK14 Q16539 1/20 0.39
▸ MET P08581 2/20 0.39
▸ KDR P35968 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ PGR P06401 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29331889 0.88 MEN1 (0.43) PIM1BIRC5KMT2AMEN1NPC1
SCHEMBL23841138 0.84 ATM (0.57) PIM1BIRC5KMT2AMEN1ALDH1A1
SCHEMBL29335418 0.84 IL4 (0.54) PIM1BIRC5KMT2AMEN1BCL2L1
SCHEMBL31695313 0.84 IL4 (0.54) PIM1BIRC5KMT2AMEN1BCL2L1
SCHEMBL29331948 0.83 SQOR (0.53) PIM1KMT2AMEN1ALDH1A1MAPT
SCHEMBL29332770 0.81 MEN1 (0.46) PIM1KMT2AMEN1NPC1MAPT
SCHEMBL31695360 0.81 IL4 (0.43) PIM1BIRC5KMT2AMEN1BCL2L1
SCHEMBL31695334 0.81 IL4 (0.43) PIM1BIRC5KMT2AMEN1ALDH1A1
SCHEMBL31695294 0.80 KDR (0.50) PIM1KMT2AMEN1ALDH1A1MAPT
SCHEMBL31695320 0.78 KDM4E (0.55) KMT2AMEN1ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317114-A1 SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 TRUSTEES OF BOSTON UNIVERSITY (US) 2021-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317114-A1 SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 IL4, IL2, IL4I1 PIM1 319/4885BIRC5 343/4885KMT2A 2798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback